• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂肪族聚酯中的肽酰化:机制和抑制策略综述。

Peptide Acylation in Aliphatic Polyesters: a Review of Mechanisms and Inhibition Strategies.

机构信息

Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Tehran, Iran.

出版信息

Pharm Res. 2024 Apr;41(4):765-778. doi: 10.1007/s11095-024-03682-6. Epub 2024 Mar 19.

DOI:10.1007/s11095-024-03682-6
PMID:38504074
Abstract

Biodegradable polyesters are widely employed in the development of controlled release systems for peptide drugs. However, one of the challenges in developing a polyester-based delivery system for peptides is the acylation reaction between peptides and polymers. Peptide acylation is an important factor that affects formulation stability and can occur during storage, in vitro release, and after drug administration. This review focuses on the mechanisms and parameters that influence the rate of peptide acylation within polyesters. Furthermore, it discusses reported strategies to minimize the acylation reaction.

摘要

可生物降解的聚酯在肽类药物的控释系统的开发中被广泛应用。然而,在开发基于聚酯的肽类药物传递系统时,面临的挑战之一是肽与聚合物之间的酰化反应。肽酰化是影响制剂稳定性的一个重要因素,它可能发生在储存、体外释放和药物给药后。本文综述了影响聚酯中肽酰化速率的机制和参数,并讨论了减少酰化反应的报道策略。

相似文献

1
Peptide Acylation in Aliphatic Polyesters: a Review of Mechanisms and Inhibition Strategies.脂肪族聚酯中的肽酰化:机制和抑制策略综述。
Pharm Res. 2024 Apr;41(4):765-778. doi: 10.1007/s11095-024-03682-6. Epub 2024 Mar 19.
2
Peptide acylation by poly(alpha-hydroxy esters).聚(α-羟基酯)介导的肽酰化反应
Pharm Res. 2002 Feb;19(2):175-81. doi: 10.1023/a:1014272816454.
3
Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres.奥曲肽的控制释放及聚(D,L-丙交酯-共-羟甲基乙交酯)与 PLGA 微球相比的肽酰化评估。
Pharm Res. 2012 Jan;29(1):110-20. doi: 10.1007/s11095-011-0517-3. Epub 2011 Jul 9.
4
Extended release microparticle-in-gel formulation of octreotide: Effect of polymer type on acylation of peptide during in vitro release.奥曲肽长效凝胶微球制剂:聚合物类型对体外释放过程中肽酰化作用的影响。
Int J Pharm. 2015 Dec 30;496(2):676-88. doi: 10.1016/j.ijpharm.2015.11.002. Epub 2015 Nov 10.
5
Acylation of peptides by lactic acid solutions.用乳酸溶液对肽进行酰化反应。
Eur J Pharm Biopharm. 2003 Jan;55(1):27-33. doi: 10.1016/s0939-6411(02)00138-8.
6
A new class of inhibitors of peptide sorption and acylation in PLGA.一类新型聚乳酸-羟基乙酸共聚物(PLGA)中肽吸附和酰化的抑制剂
J Control Release. 2009 Aug 4;137(3):179-84. doi: 10.1016/j.jconrel.2009.03.006. Epub 2009 Mar 24.
7
Minimizing acylation of peptides in PLGA microspheres.最小化 PLGA 微球中肽的酰化作用。
J Control Release. 2012 Aug 20;162(1):119-26. doi: 10.1016/j.jconrel.2012.04.022. Epub 2012 Apr 21.
8
Engineering microenvironment of biodegradable polyester systems for drug stability and release control.用于药物稳定性和释放控制的可生物降解聚酯体系的工程微环境。
Ther Deliv. 2021 Jan;12(1):37-54. doi: 10.4155/tde-2020-0113. Epub 2021 Jan 5.
9
Identification and Assessment of Octreotide Acylation in Polyester Microspheres by LC-MS/MS.通过液相色谱-串联质谱法鉴定和评估聚酯微球中奥曲肽的酰化作用
Pharm Res. 2015 Sep;32(9):3044-54. doi: 10.1007/s11095-015-1685-3. Epub 2015 Apr 2.
10
Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry.通过毛细管电泳和基质辅助激光解吸电离飞行时间质谱法监测聚乳酸-羟基乙酸共聚物(PLGA)降解微球内的肽酰化反应
J Control Release. 2003 Oct 30;92(3):291-9. doi: 10.1016/s0168-3659(03)00366-3.

本文引用的文献

1
Recent Advances in Polycaprolactones for Anticancer Drug Delivery.用于抗癌药物递送的聚己内酯的最新进展
Pharmaceutics. 2023 Jul 19;15(7):1977. doi: 10.3390/pharmaceutics15071977.
2
Polymeric in situ forming depots for long-acting drug delivery systems.聚合物原位形成储库用于长效药物传递系统。
Adv Drug Deliv Rev. 2023 Sep;200:115003. doi: 10.1016/j.addr.2023.115003. Epub 2023 Jul 6.
3
Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules.长效注射制剂技术:脆弱分子递释的挑战与机遇。
Expert Opin Drug Deliv. 2022 Aug;19(8):927-944. doi: 10.1080/17425247.2022.2105318. Epub 2022 Jul 28.
4
Therapeutic peptides: current applications and future directions.治疗性肽:当前的应用及未来方向。
Signal Transduct Target Ther. 2022 Feb 14;7(1):48. doi: 10.1038/s41392-022-00904-4.
5
PLGA/PLA-Based Long-Acting Injectable Depot Microspheres in Clinical Use: Production and Characterization Overview for Protein/Peptide Delivery.PLGA/PLA 基长效注射储库微球的临床应用:蛋白/肽给药的生产和特性概述。
Int J Mol Sci. 2021 Aug 18;22(16):8884. doi: 10.3390/ijms22168884.
6
Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method.通过溶剂蒸发法开发并鉴定与善宁长效注射剂等效的制剂。
Drug Deliv Transl Res. 2022 Mar;12(3):695-707. doi: 10.1007/s13346-021-01013-5. Epub 2021 Jul 3.
7
Impact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology.奥曲肽反离子性质对原位形成储库技术的长期稳定性和释放动力学的影响。
J Control Release. 2021 Aug 10;336:457-468. doi: 10.1016/j.jconrel.2021.06.044. Epub 2021 Jul 5.
8
Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review.基于质量源于设计的聚(乳酸-共-乙醇酸)微球的生产:综述。
Drug Deliv. 2021 Dec;28(1):1342-1355. doi: 10.1080/10717544.2021.1943056.
9
Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.载艾塞那肽聚乳酸-乙醇酸长效释放微球的性质表征及体外性能。
Eur J Pharm Biopharm. 2021 Jan;158:401-409. doi: 10.1016/j.ejpb.2020.10.008. Epub 2020 Oct 26.
10
Characterization of Octreotide-PLGA Binding by Isothermal Titration Calorimetry.用等温滴定量热法研究奥曲肽-PLGA 的结合特性。
Biomacromolecules. 2020 Oct 12;21(10):4087-4093. doi: 10.1021/acs.biomac.0c00885. Epub 2020 Sep 30.